0\" encoding=\"UTF-8\"?>\n<table frame=\"hsides\" rules=\"groups\"><thead><tr><th valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Trial name</th><th valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Number of patients enrolled</th><th valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Type of patient enrolled</th><th valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Study design</th><th valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Primary outcomes</th><th valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Secondary clinical outcomes</th><th valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Secondary MRI outcomes</th><th valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Notable adverse events</th></tr></thead><tbody><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">AFFIRM<xref rid=\"b20-ndt-13-1691\" ref-type=\"bibr\">20</xref></td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">942</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">RRMS</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Randomized placebo<break/>controlled NTZ 300 mg IV every 4 weeks versus placebo infusion every 4 weeks</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">1. NTZ reduced ARR by 68% at 1 year compared to placebo (<italic>P</italic>&lt;0.001)<break/>2. NTZ reduced the risk of sustained disability worsening at 2 years by 42% compared to placebo (<italic>P</italic>&lt;0.001)</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">1. Proportion of relapse-free patients was significantly higher in NTZ group than placebo at 1 year (77% vs 56%, <italic>P</italic>&lt;0.001) and at 2 years (67% vs 41%, <italic>P</italic>&lt;0.001)</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">1. NTZ reduced the mean number of new/enlarging T2 lesions by 83% compared to placebo over 2 years<break/>2. NTZ reduced the mean number of Gd+ lesions by 92% compared to placebo at years 1 and 2</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">1. Fatigue<break/>2. Allergic reaction<break/>3. Hypersensitivity reactions</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">SENTINEL<xref rid=\"b22-ndt-13-1691\" ref-type=\"bibr\">22</xref></td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">1,171</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">RRMS</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Randomized placebo controlled<break/>NTZ 300 mg IV every 4 weeks + IFN-beta-1a 30 microg IM weekly (combination therapy) versus IFN-beta-1a 30 microg IM weekly + placebo infusion every 4 weeks</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">1. Combination therapy reduced the ARR by 54% at 1 year compared to IFN-beta-1a 30 microg IM + placebo (maintained at 2 years) (<italic>P</italic>&lt;0.001)<break/>2. Combination therapy reduced the risk of sustained disability worsening at 2 years by 24% compared to IFN-beta-1a 30 microg IM + placebo (<italic>P</italic>=0.02)</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">1. Proportion of relapse-free patients was significantly higher in the combination therapy group compared with IFN-beta-1a 30 microg IM + placebo at 2 years (54% vs 32%, <italic>P</italic>&lt;0.001)<break/>2. Risk of relapse was 50% lower with combination therapy (HR 0.50; 95% CI 0.43-0.59; <italic>P</italic>&lt;0.001)</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">1. NTZ + IFN-beta-1a 30 microg IM reduced the mean number of new/enlarging T2 lesions by 83% compared with IFN-beta-1a 30 microg IM + placebo over 2 years<break/>2. NTZ + IFN-beta-1a 30 microg IM reduced the mean number of Gd+ lesions by 89% at 2 years compared with IFN-beta-1a 30 microg IM + placebo</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">1. Anxiety<break/>2. Pharyngitis<break/>3. Sinus congestion<break/>4. Peripheral edema<break/>5. PML (n=2 at the time of publication)</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">ASCEND<xref rid=\"b24-ndt-13-1691\" ref-type=\"bibr\">24</xref></td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">887</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">SPMS</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Randomized placebo controlled NTZ 300 mg IV every 4 weeks versus placebo infusion every 4 weeks</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">1. No significant difference in disability progression between the NTZ and placebo group (<italic>P</italic>=0.287)</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">1.